ImetelChat

Geron Announces Presentations at American Society of Hematology Annual Meeting Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes to be Presented MENLO PARK, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that four abstracts relate...

Nice! Plus the strat of expanded Part 1 of IMerge. Expanded Part 1 of IMerge is Open for Patient Enrollment MENLO PARK, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designati...

MENLO PARK, Calif., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2017, on Wednesday, November 1, 2017, after the market close. Geron’s management will also host a conference call for analysts and inves...

Indeed, Cheng. It is for testing purposes.

Method for identification of sensitivity of a patient to telomerase inhibition therapy REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Ser. No. 13/124,376, filed Apr. 14, 2011, which is a 371 of PCT Application Serial No. PCT/US09/60526, filed Oct. 13, 2009, which claim...

Nice post, BP. I share your vision. The things you mention are simple and solid, derived from what we actually know from various publications and telco's. Btw: ESA's only boost red cell production for a while. Or never, because still a large portion of MF and MDS patients don't respond to ESA's (suc...

Actually I think it will be more than one step....

You're welcome, Ryan!

Indeed, the latest telco seems to tell us that JnJ is closing in on its target and is carefully choosing its gateway to the market. These early biotech tunnels can be long and dangerous, and proper lighting is not always available....

Done. It is in the News and the Commercial section.

another great comment from Hoosier (SA): 1) Contractually, Janssen could've postponed the primary analysis as long as they desired. Thus, by agreeing to the 3Q18 cut-off date, Janssen is showing some consideration / compassion for Geron's position. 2) I suspect Janssen's recent discussions with FDA ...

Repost from sdrawkcabeman (YHMB, yesterday) Drug development is an exercise in strategic planning. Tracing the root of the Imet program, we see the strategy being continually refined and the drug proven to be active repeatedly across multiple conditions, and this quite stunning and clear signal in t...

1 Aug 2017 IMerge Substantial results are observed in the 13 patients subgroup (non-del5q and naïve to HMA): 53.7% achieved 8+ weeks of TI. The non-del8q subgroup represents approximately 85% of all the MDS patients. It seems the imetelstat will beat Best Available Therapy in this group. 20 new pati...

Second comment from Hoosier on SA today: 1) Our 'good problem to have' within IMbark continues as patients remain alive to the extent they can't assess median overall survival. This has been the source of delay in the IMbark primary analysis and subsequent Continuation Decision. Again, it's a good p...

Response from Hoosier on SA on the press release: 1) Lenalidomide's MDS approval is limited to patients with a deletion 5q cytogenetic abnormality. Lenalidomide's safety and efficacy were demonstrated in one single-arm, multicenter clinical trial of 148 patients. The primary endpoint was RBC transfu...

Geron Announces Updates to Imetelstat Clinical Development Conference Call Scheduled for 8:00 a.m. ET on Tuesday, August 1 MENLO PARK, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced updates to the clinical development plans for IMerge and IMbark, the ongoi...

Just a reminder for those who want to join, but who found out that the normal registration process has been disabled. Just send an email to info@imetelstat.eu and I will make an account for you.

done

Thanks, Bio. Interesting article. I will upload it asap.

Bio, thanks for kicking this off here. I agree with your observations. The Mayo Pilot hasn't been designed for getting approval, unlike IMbark and IMerge. My take is that extending the study-end therefor is not directly related with the approval process and has more to do with studying long term eff...

Hi Sargasso, it certainly is an interesting question, that I am not really able to answer. Certainly an above average of shares changed hands on the example you gave, but I have no idea who buys and sells and why. There are many of such examples, with PPS going up as well as down. Basically I don't ...